MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients

Nancy Kim¹*, Wei Gao¹, Xiaoli Shirley Glasgow¹, Leticia Arrington¹, Tami Crumley¹, Marie-Francoise Temam¹, Edward Gane², Wouter Haazen³, Serghei Popa⁴, Eric Sicard⁵, Catherine Stedman⁶, William L. Marshall¹, John Sullivan-Bolyai¹, and Eugene E. Marcantonio¹

¹Merck & Co., Kenilworth, NJ, USA ²Auckland City Hospital, Auckland, NZ ³SGS Life Sciences Services, Antwerp, Belgium ⁴Republican Clinical Hospital, Chisinau, Moldova ⁵Algorithme Pharma, Montreal, Canada ⁶Christchurch Clinical Studies Trust, Christchurch, NZ

17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy
June 10, 2016
Washington, DC
Disclosures and Acknowledgments

• These authors are employees of Merck
• Disclosures: CS – advisory boards/speakers bureau for Abbvie, Gilead Sciences, and MSD; JSB – current employee of Contravir
• The design, study conduct, analysis, and financial support of the trial were provided by Merck.
• We extend our gratitude to SGS Life Sciences, and the patients, investigators, and site personnel who participated in this study.
Background

- MK-3682 is a potent pan-genotypic inhibitor of Hepatitis C Virus (HCV) non-structural protein 5B (NS5B) that is being developed for the treatment of HCV infection.
- MK-3682 is expected to exhibit a high barrier to resistance.
- MK-3682 has pharmacokinetics supportive of once-daily oral administration.
- Clinical studies are evaluating the pharmacokinetics of the parent prodrug (MK-3682) and its major circulating metabolite (M6) that may inform the efficacy and safety of MK-3682 in clinical development.
Objectives

• To evaluate the antiviral activity, pharmacokinetics, and safety of MK-3682 administered as 7 days of monotherapy in non-cirrhotic patients with genotype (GT) -1, -2, or -3, HCV infection.

• To evaluate the antiviral activity, pharmacokinetics, and safety of MK-3682 administered as 7 days of monotherapy in HCV GT1-infected patients with mild hepatic impairment (Child-Pugh A).
Methods

- Phase 1b, randomized, placebo-controlled study
- Eighty (80) adults, with HCV GT-1, -2, or -3 infection (HCV RNA ≥ 5.0 log_{10} IU/mL) without clinical evidence of cirrhosis, randomized to receive:
  - placebo or MK-3682 from 50 to 400 mg (GT1) (capsule)
  - open-label MK-3682 300 to 450 mg (GT1) (tablet) or 50 to 300 mg (GT2 or GT3) once daily for 7 days (capsule)
- Pharmacokinetic (PK) sampling for 12 days
- Viral load sampling for 35 days
- Safety and tolerability were evaluated using laboratory values, ECGs, and evaluation of adverse events (AEs)
Methods

- Eleven (11) adults with HCV GT1 infection and mild hepatic impairment (Child-Pugh Score A) randomized to receive open-label MK-3682 300 or 450 mg once daily for 7 days
- Pharmacokinetic (PK) sampling for 12 days
- Viral load sampling for 35 days
- Safety and tolerability were evaluated using laboratory values, ECGs, and evaluation of adverse events (AEs)
Change from baseline $\log_{10}$ HCV RNA over time after receiving multiple doses of MK-3682 or placebo for 7 days -- overall

Hours since first drug intake

- 150 (3x50 mg (capsule) MK-3682 QD x 7 days (n=9)
- 250 (5x50 mg (capsule) MK-3682 QD x 7 days (n=8)
- 300 (2x150 mg (tablet) MK-3682 QD x 7 days (n=7)
- 300 (6x50 mg (capsule) MK-3682 QD x 7 days (n=17)
- 450 (8x50 mg (capsule) MK-3682 QD x 7 days (n=7)
- 450 (3x150 mg (tablet) MK-3682 QD x 7 days (n=7)
- 50 (2x25 mg (capsule) MK-3682 QD x 7 days (n=10)
- placebo (capsule) x 7 days (pooled) (n=8)
Change from baseline $\log_{10}$ HCV RNA over time after receiving multiple doses of MK-3682 or placebo for 7 days – GT1
Change from baseline $\log_{10} HCV$ RNA over time after receiving multiple doses of MK-3682 for 7 days – GT2

Hours since first drug intake
- 150 (3x50) mg (capsule) MK-3682 QD x 7 days (n=1)
- 300 (6x50) mg (capsule) MK-3682 QD x 7 days (n=2)
Change from baseline log_{10} HCV RNA over time after receiving multiple doses of MK-3682 for 7 days – GT3
Change from baseline $\log_{10}$ HCV RNA over time after receiving multiple doses of MK-3682 for 7 days – mild hepatic insufficiency, GT1
Dose-Response Relationship

MK-3682 Dose Response (Mean +/- SE)

- **Flag**
  - GT1 Cap
  - GT1 Tab
  - GT23 Cap

- **Maximum Log10 Viral Load Decline**

- **Dose (mg)**
  - 0
  - 100
  - 200
  - 300
  - 400

- **Mean +/- SE**
Pharmacokinetics

• After QD administrations for 7 days in fasted state in HCV-infected patients, MK-3682 was rapidly absorbed ($t_{\text{max}} < 2\text{h}$), with $t_{\text{max}}$ for its major metabolite M6 <4h.

• $t_{1/2}$ for MK-3682 was <3h and $t_{1/2}$ for M6 were ~30h. Consistent with the $t_{1/2}$, MK-3682 exhibited no accumulation, and accumulation ratio for M6 was ~1.5 fold.

• MK-3682 PK were largely dose proportional while M6 PK were less than dose proportional.

• tablet vs. capsule in HCV-infected patients:
  – bioavailability of MK-3682 (both $C_{\text{max}}$ and AUC) was lower with the tablet formulation, with $C_{\text{max}}$ and AUC$_{0-t}$ reduced by 60% and 34%.
  – M6 exposures were comparable between the tablet formulation and the reference capsule formulation.
  – The rate of absorption and the rate of elimination were similar.

• Mild Hepatic impairment in HCV-infected patients:
  – MK-3682 $C_{\text{max}}$ and AUC$_{0-t}$ increased by 29% and 22%, respectively
  – M6 steady-state $C_{\text{max}}$ and AUC$_{0-24\text{h}}$ were similar
Safety findings (1)

- MK-3682 was well-tolerated, with all AEs transient and mild in intensity.
- In non-cirrhotic HCV-infected patients receiving multiple doses of MK-3682:
  - TEAEs occurred in 6 (67%) patients receiving placebo and 46 (65%) patients receiving MK-3682.
  - Headache was the most frequently observed TEAE.
    - 3 patients (33%) receiving placebo, 2 patients (18%) receiving 50 mg capsules, 0 patients receiving 150 mg capsules, 4 patients (50%) receiving 250 mg capsules, 2 patients (11%) receiving 300 mg capsules, 4 patients (50%) receiving 400 mg capsules, 3 patients (38%) receiving 300 mg tablets, and no patients receiving 450 mg tablets.
Safety findings (2)

- In HCV-infected patients with mild hepatic impairment receiving multiple doses of MK-3682, the most commonly reported TEAEs were headache (2 [18%] patients) and nasopharyngitis (2 [18%] patients).
- No clinically significant laboratory abnormalities or changes in vital signs or ECG readings in all groups.
Conclusions

• MK-3682 exhibits potent antiviral activity during 7 days of monotherapy in non-cirrhotic patients with GT-1, -2, and GT-3 chronic HCV infection and in patients with mild hepatic impairment with GT-1 chronic HCV infection.

• Exposure-response analyses suggest that antiviral activity of MK-3682 at a 450 mg dose of the tablet formulation is largely maintained at the plateau level.

• The safety, pharmacokinetics, and antiviral data support the continued clinical investigation of MK-3682 at a dose of 450 mg as a once-daily component of an all-oral, interferon-free regimen for the treatment of chronic HCV-infection.